questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-Serine-Threonine Kinases
Proline-directed protein kinases
Kinases cyclines-dépendantes
Kinases CDC2-CDC28
Kinases CDC2-CDC28 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Kinases CDC2-CDC28 : Questions médicales les plus fréquentes",
"headline": "Kinases CDC2-CDC28 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Kinases CDC2-CDC28 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-18",
"dateModified": "2025-04-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Kinases CDC2-CDC28"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Kinases cyclines-dépendantes",
"url": "https://questionsmedicales.fr/mesh/D018844",
"about": {
"@type": "MedicalCondition",
"name": "Kinases cyclines-dépendantes",
"code": {
"@type": "MedicalCode",
"code": "D018844",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.646.500"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protéine-kinase CDC28 de S. cerevisiae",
"alternateName": "CDC28 Protein Kinase, S cerevisiae",
"url": "https://questionsmedicales.fr/mesh/D017489",
"about": {
"@type": "MedicalCondition",
"name": "Protéine-kinase CDC28 de S. cerevisiae",
"code": {
"@type": "MedicalCode",
"code": "D017489",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.646.500.500.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Kinase-5 cycline-dépendante",
"alternateName": "Cyclin-Dependent Kinase 5",
"url": "https://questionsmedicales.fr/mesh/D051360",
"about": {
"@type": "MedicalCondition",
"name": "Kinase-5 cycline-dépendante",
"code": {
"@type": "MedicalCode",
"code": "D051360",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.646.500.500.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Kinases CDC2-CDC28",
"alternateName": "CDC2-CDC28 Kinases",
"code": {
"@type": "MedicalCode",
"code": "D042846",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Rebecca B Riggins",
"url": "https://questionsmedicales.fr/author/Rebecca%20B%20Riggins",
"affiliation": {
"@type": "Organization",
"name": "Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, 20057, USA."
}
},
{
"@type": "Person",
"name": "Zhengqing Yang",
"url": "https://questionsmedicales.fr/author/Zhengqing%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Shanghai Yangsi Hospital, Shanghai, China (mainland)."
}
},
{
"@type": "Person",
"name": "Hui Cheng",
"url": "https://questionsmedicales.fr/author/Hui%20Cheng",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Shanghai Yangsi Hospital, Shanghai, China (mainland)."
}
},
{
"@type": "Person",
"name": "Yazhou Zhang",
"url": "https://questionsmedicales.fr/author/Yazhou%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Shanghai Yangsi Hospital, Shanghai, China (mainland)."
}
},
{
"@type": "Person",
"name": "Yan Zhou",
"url": "https://questionsmedicales.fr/author/Yan%20Zhou",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Shanghai Yangsi Hospital, Shanghai, China (mainland)."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.",
"datePublished": "2023-03-04",
"url": "https://questionsmedicales.fr/article/36880088",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/jacamr/dlad011"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China.",
"datePublished": "2022-08-18",
"url": "https://questionsmedicales.fr/article/36059480",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.901176"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.",
"datePublished": "2022-09-09",
"url": "https://questionsmedicales.fr/article/36088952",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/S2352-4642(22)00245-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "'I probably wouldn't want to talk about anything too personal': A qualitative exploration of how issues of privacy, confidentiality and surveillance in the home impact on access and engagement with online services and spaces for care-experienced young people.",
"datePublished": "2023-10-19",
"url": "https://questionsmedicales.fr/article/37873026",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/03085759231203019"
}
},
{
"@type": "ScholarlyArticle",
"name": "Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.",
"datePublished": "2022-08-27",
"url": "https://questionsmedicales.fr/article/36145549",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/pharmaceutics14091801"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-Serine-Threonine Kinases",
"item": "https://questionsmedicales.fr/mesh/D017346"
},
{
"@type": "ListItem",
"position": 6,
"name": "Proline-directed protein kinases",
"item": "https://questionsmedicales.fr/mesh/D038461"
},
{
"@type": "ListItem",
"position": 7,
"name": "Kinases cyclines-dépendantes",
"item": "https://questionsmedicales.fr/mesh/D018844"
},
{
"@type": "ListItem",
"position": 8,
"name": "Kinases CDC2-CDC28",
"item": "https://questionsmedicales.fr/mesh/D042846"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Kinases CDC2-CDC28 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Kinases CDC2-CDC28",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Kinases CDC2-CDC28",
"description": "Comment diagnostiquer une dysfonction des kinases CDC2-CDC28 ?\nQuels tests sont utilisés pour évaluer l'activité des kinases CDC2-CDC28 ?\nLes biopsies peuvent-elles aider au diagnostic ?\nQuels marqueurs biologiques sont associés aux kinases CDC2-CDC28 ?\nLes tests génétiques sont-ils nécessaires pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D042846?mesh_terms=Probability&page=273#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Kinases CDC2-CDC28",
"description": "Quels symptômes indiquent une anomalie des kinases CDC2-CDC28 ?\nLes troubles de la division cellulaire sont-ils liés aux kinases CDC2-CDC28 ?\nPeut-on observer des anomalies morphologiques cellulaires ?\nLes cancers sont-ils liés aux dysfonctionnements des kinases CDC2-CDC28 ?\nY a-t-il des signes cliniques spécifiques à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D042846?mesh_terms=Probability&page=273#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Kinases CDC2-CDC28",
"description": "Peut-on prévenir les dysfonctionnements des kinases CDC2-CDC28 ?\nY a-t-il des mesures préventives spécifiques ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nL'exercice physique peut-il aider à prévenir des anomalies ?\nLes vaccinations ont-elles un impact sur les kinases ?",
"url": "https://questionsmedicales.fr/mesh/D042846?mesh_terms=Probability&page=273#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Kinases CDC2-CDC28",
"description": "Quels traitements ciblent les kinases CDC2-CDC28 ?\nLes thérapies géniques sont-elles une option ?\nComment les inhibiteurs de kinases sont-ils administrés ?\nY a-t-il des effets secondaires aux traitements ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D042846?mesh_terms=Probability&page=273#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Kinases CDC2-CDC28",
"description": "Quelles complications peuvent survenir avec des anomalies des kinases ?\nLes anomalies des kinases peuvent-elles affecter d'autres systèmes ?\nY a-t-il des risques de résistance aux traitements ?\nLes complications sont-elles réversibles ?\nComment gérer les complications liées aux kinases ?",
"url": "https://questionsmedicales.fr/mesh/D042846?mesh_terms=Probability&page=273#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Kinases CDC2-CDC28",
"description": "Quels sont les principaux facteurs de risque pour les anomalies des kinases ?\nL'âge est-il un facteur de risque ?\nLe tabagisme influence-t-il les kinases ?\nY a-t-il un lien entre l'alimentation et les kinases ?\nLe stress peut-il affecter les kinases ?",
"url": "https://questionsmedicales.fr/mesh/D042846?mesh_terms=Probability&page=273#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des kinases CDC2-CDC28 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests génétiques et des analyses de protéines spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des kinases CDC2-CDC28 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques et des dosages enzymatiques sont utilisés pour mesurer leur activité."
}
},
{
"@type": "Question",
"name": "Les biopsies peuvent-elles aider au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les biopsies peuvent révéler des anomalies dans l'expression des kinases CDC2-CDC28."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux kinases CDC2-CDC28 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs comme cyclines et phosphorylations spécifiques sont souvent analysés."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils nécessaires pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier des mutations affectant les kinases CDC2-CDC28."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une anomalie des kinases CDC2-CDC28 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la croissance cellulaire anormale ou des troubles du cycle cellulaire peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les troubles de la division cellulaire sont-ils liés aux kinases CDC2-CDC28 ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans ces kinases peuvent entraîner des troubles de la division cellulaire."
}
},
{
"@type": "Question",
"name": "Peut-on observer des anomalies morphologiques cellulaires ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies morphologiques peuvent être observées dans les cellules affectées."
}
},
{
"@type": "Question",
"name": "Les cancers sont-ils liés aux dysfonctionnements des kinases CDC2-CDC28 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements peuvent contribuer à la carcinogenèse et à la progression tumorale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques spécifiques à surveiller ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'hyperplasie ou des anomalies dans le cycle cellulaire doivent être surveillés."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des kinases CDC2-CDC28 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un mode de vie sain et la réduction des facteurs de risque environnementaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages réguliers et une surveillance des antécédents familiaux sont recommandés."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut contribuer à la santé cellulaire et à la prévention."
}
},
{
"@type": "Question",
"name": "L'exercice physique peut-il aider à prévenir des anomalies ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier favorise la santé cellulaire et peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Les vaccinations ont-elles un impact sur les kinases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent réduire le risque de cancers associés aux dysfonctionnements des kinases."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les kinases CDC2-CDC28 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques des kinases sont utilisés pour traiter les dysfonctionnements associés."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques sont-elles une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique peut corriger des mutations affectant les kinases CDC2-CDC28."
}
},
{
"@type": "Question",
"name": "Comment les inhibiteurs de kinases sont-ils administrés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale ou intraveineuse, selon le médicament."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme la toxicité cellulaire peuvent survenir avec certains traitements."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des kinases."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des kinases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme le cancer, des troubles métaboliques et des anomalies cellulaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les anomalies des kinases peuvent-elles affecter d'autres systèmes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent avoir des répercussions sur le système immunitaire et d'autres systèmes organiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de résistance aux traitements ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans les kinases peuvent entraîner une résistance aux traitements ciblés."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux kinases ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des ajustements thérapeutiques."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les anomalies des kinases ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques, l'exposition à des agents cancérigènes et des habitudes de vie."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'anomalies des kinases augmente avec l'âge en raison de l'accumulation de mutations."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les kinases ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour des anomalies dans les kinases CDC2-CDC28."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien entre l'alimentation et les kinases ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en graisses et en sucres peut augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter les kinases ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut influencer l'expression et l'activité des kinases CDC2-CDC28."
}
}
]
}
]
}
To assess the relationship between renal function and efficacy/safety of imipenem/cilastatin/relebactam for the treatment of hospital-acquired/ventilator-associated pneumonia (HABP/VABP) from RESTORE-...
Adults with HABP/VABP were randomized 1:1 to IV imipenem/cilastatin/relebactam 1.25 g or piperacillin/tazobactam 4.5 g every 6 h for 7-14 days. Initial doses were selected by CL...
The modified ITT population comprised those with normal renal function (...
Prescribing information-defined dose adjustments in participants with baseline RI and full dosing of imipenem/cilastatin/relebactam 1.25 g every 6 h for participants with normal renal function or augm...
To identify less invasive and easily applicable serum cytokine-derived biomarkers which contribute to the diagnostic utility and risk assessment ability of the prostate health index (PHI) based multiv...
Serum 45 cytokines screening was performed in a small training cohort consisting of 10 sera by Luminex liquid array-based multiplexed immunoassays and identified TRAIL and IL-10 as new biomarkers for ...
TRAIL and IL-10 were identified as potential serum biomarkers for AG PCa detection by the result of multi-cytokines screening in the univariate analysis, while multivariable logistic regression confir...
We suggest a significant advantage for the PHI-based multivariate combinations of serum TRAIL and IL-10 comparing to PHI or other serum-derived biomarkers alone in the detection and risk stratificatio...
Switching from intravenous antibiotic therapy to oral antibiotic therapy among neonates is not yet practised in high-income settings due to uncertainties about exposure and safety. We aimed to assess ...
In this multicentre, randomised, open-label, non-inferiority trial, patients were recruited at 17 hospitals in the Netherlands. Neonates (postmenstrual age ≥35 weeks, postnatal age 0-28 days, bodyweig...
Between Feb 8, 2018 and May 12, 2021, 510 neonates were randomly assigned (n=255 oral amoxicillin-clavulanic group; n=255 intravenous antibiotic group). After excluding those who withdrew consent (n=4...
An early intravenous-to-oral antibiotic switch with amoxicillin-clavulanic acid is non-inferior to a full course of intravenous antibiotics in neonates with probable bacterial infection and is not ass...
The Netherlands Organization for Health Research and Development, Innovatiefonds Zorgverzekeraars, and the Sophia Foundation for Scientific Research....
This paper draws on a qualitative interview-based study that explored online mental health and wellbeing interventions and services for care-experienced young people. The study involved young people (...
The World Health Organization recommends pre-exposure prophylaxis (PrEP) for individuals at substantial risk of HIV infection. The aim of this analysis is to quantify the individual risk of HIV infect...
The risk and survival of patients with non-small cell lung cancer (NSCLC) with pre-existing autoimmune disorders (AIDs) receiving immune checkpoint blockade (ICB) therapy have not been clearly establi...
This multi-institutional, retrospective cohort study was conducted in collaboration with 20 centers in Japan....
In total, 229 patients with advanced or recurrent NSCLC and pre-existing AID, with or without ICB treatment from January 2010-February 2020, were included and analyzed. Among 69 patients who received ...
These findings revealed a novel risk factor for AID flares following ICB treatment, that is the diagnosis of NSCLC within 1 year of AID diagnosis, and showed that ICBs may improve survival in this pop...
Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has impo...
Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Ander...
Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, p<0·005); pre-RT dental extractions was associated to ...
This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the proba...
This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation....
Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antena...
WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phospha...
This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmaco...
ISRCTN11434567 . Registered on 7 June 2021....